SCHEMBL12796909

SCHEMBL12796909

Cc1cn(-c2ccc3c(c2)-c2ncc(NC(=O)c4c(F)cccc4F)nc2CCC3)cn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR142 Q7Z601 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ PSEN1 P49768 1/20 0.37
▸ PSEN2 P49810 1/20 0.37
▸ APH1B Q8WW43 1/20 0.37
▸ NCSTN Q92542 1/20 0.37
▸ APH1A Q96BI3 1/20 0.37
▸ PSENEN Q9NZ42 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ USP30 Q70CQ3 2/20 0.35
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ RORC P51449 3/20 0.34
▸ IL2 P60568 2/20 0.34
▸ NR2E1 Q9Y466 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ GFER P55789 1/20 0.34
▸ MAOA P21397 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12796898 0.90 IL2 (0.36) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL12797006 0.86 NPC1 (0.38) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL12848757 0.81 MEN1 (0.43) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL14222427 0.79 MEN1 (0.43) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL12848953 0.76 ADORA2B (0.44) CYP3A4MEN1KMT2AALDH1A1GFER
SCHEMBL12848460 0.75 GPR142 (0.37) GPR142CYP3A4PSEN1PSEN2APH1B
SCHEMBL14172604 0.75 RAB9A (0.45) CYP3A4MEN1KMT2ANPC1RAB9A
SCHEMBL12796745 0.71 NPC1 (0.46) CYP3A4MEN1KMT2ANPC1RAB9A
SCHEMBL12848575 0.71 LDLR (0.42) GPR142USP30NPC1RAB9ASMN1; SMN2
SCHEMBL12796908 0.69 STIM1 (0.41) MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110052643-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2011-03-03 — — US disclosed
US-20110052643-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2011-03-03 — — US disclosed
WO-2009089305-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2009-07-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110052643-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES TSLP, NFATC1, IL5 GPR142 1957/4885CYP3A4 622/4885PSEN1 3587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback